Bayesian Capital Management’s GSK GSK Stock Holding History

Bayesian Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$949K	Buy	+18,100	New	+$957K	0.61%	47
2025 Q4	–	Sell	-10,295	Closed	-$444K	–	298
2025 Q3	$444K	Buy	+10,295	New	+$402K	0.09%	301
2025 Q2	–	Sell	-15,837	Closed	-$614K	–	679
2025 Q1	$614K	Buy	15,837 +1,800	+13%	+$65.9K	0.1%	260
2024 Q4	$475K	Buy	+14,037	New	+$505K	0.06%	383
2023 Q3	–	Sell	-10,500	Closed	-$374K	–	816
2023 Q2	$374K	Buy	+10,500	New	+$377K	0.04%	480
2023 Q1	–	Sell	-24,320	Closed	-$855K	–	911
2022 Q4	$855K	Sell	24,320 -27,000	-53%	-$899K	0.12%	219
2022 Q3	$1.51M	Buy	+51,320	New	+$1.95M	0.31%	74
2021 Q2	–	Sell	-27,860	Closed	-$1.24M	–	500
2021 Q1	$1.24M	Buy	+27,860	New	+$1.26M	0.29%	89
2016 Q3	–	Sell	-5,584	Closed	-$303K	–	409
2016 Q2	$303K	Buy	5,584 +1,032	+23%	+$54.4K	0.18%	233
2016 Q1	$231K	Sell	4,552 -1,345	-23%	-$67K	0.22%	238
2015 Q4	$297K	Buy	+5,897	New	+$301K	0.43%	101

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bayesian Capital Management's GSK Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in GSK (GSK) in Q2 2026: 18,100 shares worth $949K. The stake represents 0.61% of the portfolio and ranks #47 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in GSK as recently as Q3 2025.

Bayesian Capital Management first reported a position in GSK in Q4 2015 and has held it in 11 quarters since. The position peaked at $1.51M in Q3 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bayesian Capital Management held 18,100 shares of GSK worth $949K as of Q2 2026.
GSK was a new Bayesian Capital Management position in Q2 2026.
GSK made up 0.61% of Bayesian Capital Management's portfolio in Q2 2026, its #47 holding.
Bayesian Capital Management first reported a position in GSK in Q4 2015 and has held it in 11 quarters since.
Bayesian Capital Management's GSK position peaked at $1.51M in Q3 2022.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.